Sumit Arora

Sumit Arora

Auto-generated profile, based on publicly available information

Sumit Arora

Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in International Journal of Nanomedicine
Verified
Journal Article
Open access
MWMuhammad Wahajuddin
Muhammad Wahajuddin
SASumit Arora
Sumit Arora
Peer reviewed article authored by (Wahajuddin, Arora S). Read article or submit your manuscript for publishing.

11 April 2024 in Molecular Pharmaceutics
Verified
Journal Article
Open access
CMClaire Mackie
Claire Mackie
SASumit Arora
Sumit Arora
PSPaul Seo
Paul Seo
RMRebecca Moody
Rebecca Moody
BRBhagwant Rege
Bhagwant Rege
GRGregory Rullo
Gregory Rullo
Physiologically based biopharmaceutics modeling (PBBM) is used to elevate drug product quality by providing a more accurate and holistic understanding of how drugs interact with the human body. These models are based on the integration of physiological, pharmacological, and pharmaceutical data to simulate and predict drug behavior in vivo. Effective utilization of PBBM requires a consistent approach to model development, verification, validation, and application. Currently, only one country has a draft guidance document for PBBM, whereas other major regulatory authorities have had limited experience with the review of PBBM. To address this gap, industry submitted confidential PBBM case studies to be reviewed by the regulatory agencies; software companies committed to training. PBBM cases were independently and collaboratively discussed by regulators, and academic colleagues participated in some of the discussions. Successful bioequivalence "safe space" industry case examples are also presented. Overall, six regulatory agencies were involved in the case study exercises, including ANVISA, FDA, Health Canada, MHRA, PMDA, and EMA (experts from Belgium, Germany, Norway, Portugal, Spain, and Sweden), and we believe this is the first time such a collaboration has taken place. The outcomes were presented at this workshop, together with a participant survey on the utility and experience with PBBM submissions, to discuss the best scientific practices for developing, validating, and applying PBBMs. The PBBM case studies enabled industry to receive constructive feedback from global regulators and highlighted clear direction for future PBBM submissions for regulatory consideration.

20 February 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
VKVarun Kushwah
Varun Kushwah
SASumit Arora
Sumit Arora
MKMiklós Katona
Miklós Katona
DMDattatray Modhave
Dattatray Modhave
Eleonore FröhlichEleonore Fröhlich
Eleonore Fröhlich
APAmrit Paudel
Amrit Paudel
The present work evaluates the food effect on the absorption of rivaroxaban (Riva), a BCS II drug, from the orally administered commercial immediate-release tablet (Xarelto IR) using physiologically based pharmacokinetic (PBPK) and conventional in vitro–in vivo correlation (IVIVC) models. The bioavailability of Riva upon oral administration of Xarelto IR tablet is reported to exhibit a positive food effect. The PBPK model for Riva was developed and verified using the previously reported in vivo data for oral solution (5 and 10 mg) and Xarelto IR tablet (5 and 10 mg dose strength). Once the PBPK model was established, the in vivo performance of the tablet formulation with the higher dose strength (Xarelto IR tablet 20 mg in fasted and fed state) was predicted using the experimentally obtained data of in vitro permeability, biorelevant solubility and in vitro dynamic dissolution data using United States Pharmacopeia (USP) IV flow-through cell apparatus. In addition, the mathematical IVIVC model was developed using the in vitro dissolution and in vivo profile of 20 mg strength Xarelto IR tablet in fasted condition. Using the developed IVIVC model, the pharmacokinetic (PK) profile of the Xarelto IR tablet in fed condition was predicted and compared with the PK parameters obtained via the PBPK model. A virtual in vivo PK study was designed using a single-dose, 3-treatment cross-over trial in 50 subjects to predict the PK profile of the Xarelto® IR tablet in the fed state. Overall, the results obtained from the IVIVC model were found to be comparable with those from the PBPK model. The outcome from both models pointed to the positive food effect on the in vivo profile of the Riva. The developed models thus can be effectively extended to establish bioequivalence for the marketed and novel complex formulations of Riva such as amorphous solid dispersions.

19 May 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
SASumit Arora
Sumit Arora
APAmita Pansari
Amita Pansari
PKPeter Kilford
Peter Kilford
MJMasoud Jamei
Masoud Jamei
IGIain Gardner
Iain Gardner
DTDavid B. Turner
David B. Turner

1 July 2024 in Molecular Pharmaceutics
Verified
Journal Article
Open access
XPXavier J.H. Pepin
Xavier J.H. Pepin
SASumit Arora
Sumit Arora
LBLuiza Borges
Luiza Borges
MCMario Cano-Vega
Mario Cano-Vega
TCTessa Carducci
Tessa Carducci
PSPaul Seo
Paul Seo
This Article shares the proceedings from the August 29th, 2023 (day 1) workshop "Physiologically Based Biopharmaceutics Modeling (PBBM) Best Practices for Drug Product Quality: Regulatory and Industry Perspectives". The focus of the day was on model parametrization; regulatory authorities from Canada, the USA, Sweden, Belgium, and Norway presented their views on PBBM case studies submitted by industry members of the IQ consortium. The presentations shared key questions raised by regulators during the mock exercise, regarding the PBBM input parameters and their justification. These presentations also shed light on the regulatory assessment processes, content, and format requirements for future PBBM regulatory submissions. In addition, the day 1 breakout presentations and discussions gave the opportunity to share best practices around key questions faced by scientists when parametrizing PBBMs. Key questions included measurement and integration of drug substance solubility for crystalline vs amorphous drugs; impact of excipients on apparent drug solubility/supersaturation; modeling of acid-base reactions at the surface of the dissolving drug; choice of dissolution methods according to the formulation and drug properties with a view to predict the in vivo performance; mechanistic modeling of in vitro product dissolution data to predict in vivo dissolution for various patient populations/species; best practices for characterization of drug precipitation from simple or complex formulations and integration of the data in PBBM; incorporation of drug permeability into PBBM for various routes of uptake and prediction of permeability along the GI tract.

30 September 2024 in Molecular Pharmaceutics
Verified
Journal Article
Open access
THTycho Heimbach
Tycho Heimbach
FTFlora Musuamba Tshinanu
Flora Musuamba Tshinanu
KRKimberly Raines
Kimberly Raines
LBLuiza Borges
Luiza Borges
SKShinichi Kijima
Shinichi Kijima
CMClaire Mackie
Claire Mackie
The proceedings from the 30th August 2023 (Day 2) of the workshop "Physiologically Based Biopharmaceutics Models (PBBM) Best Practices for Drug Product Quality: Regulatory and Industry Perspectives" are provided herein. Day 2 covered PBBM case studies from six regulatory authorities which provided considerations for model verification, validation, and application based on the context of use (COU) of the model. PBBM case studies to define critical material attribute (CMA) specification settings, such as active pharmaceutical ingredient (API) particle size distributions (PSDs) were shared. PBBM case studies to define critical quality attributes (CQAs) such as the dissolution specification setting or to define the bioequivalence safe space were also discussed. Examples of PBBM using the credibility assessment framework, COU and model risk assessment, as well as scientific learnings from PBBM case studies are provided. Breakout session discussions highlighted current trends and barriers to application of PBBMs including: (a) PBBM credibility assessment framework and level of validation, (b) use of disposition parameters in PBBM and points to consider when iv data are not available, (c) conducting virtual bioequivalence trials and dealing with variability, (d) model acceptance criteria, and (e) application of PBBMs for establishing safe space and failure edges.